ES2970401T3 - Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza - Google Patents

Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza Download PDF

Info

Publication number
ES2970401T3
ES2970401T3 ES13749329T ES13749329T ES2970401T3 ES 2970401 T3 ES2970401 T3 ES 2970401T3 ES 13749329 T ES13749329 T ES 13749329T ES 13749329 T ES13749329 T ES 13749329T ES 2970401 T3 ES2970401 T3 ES 2970401T3
Authority
ES
Spain
Prior art keywords
viral
cells
patient
das181
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13749329T
Other languages
English (en)
Spanish (es)
Inventor
Ron Moss
Tiejun Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Application granted granted Critical
Publication of ES2970401T3 publication Critical patent/ES2970401T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES13749329T 2012-02-17 2013-02-19 Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza Active ES2970401T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600545P 2012-02-17 2012-02-17
US201261727627P 2012-11-16 2012-11-16
PCT/US2013/026754 WO2013123521A1 (en) 2012-02-17 2013-02-19 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Publications (1)

Publication Number Publication Date
ES2970401T3 true ES2970401T3 (es) 2024-05-28

Family

ID=48984833

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13749329T Active ES2970401T3 (es) 2012-02-17 2013-02-19 Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza

Country Status (9)

Country Link
US (5) US20130280332A1 (enExample)
EP (1) EP2841092B1 (enExample)
JP (1) JP2015508780A (enExample)
CN (2) CN109529026A (enExample)
AU (3) AU2013221230A1 (enExample)
CA (1) CA2864746A1 (enExample)
ES (1) ES2970401T3 (enExample)
IL (2) IL234116B (enExample)
WO (1) WO2013123521A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CA2964629A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
BR112017009440A2 (pt) * 2014-11-06 2017-12-19 Dana Farber Cancer Inst Inc uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)
WO2016200916A1 (en) * 2015-06-08 2016-12-15 Ansun Biopharma, Inc. Treatment of human metapneumovirus
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
WO2017184999A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
AU2020391178A1 (en) * 2019-11-25 2022-06-09 Ansun Biopharma, Inc. Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
JP2024540218A (ja) 2021-11-02 2024-10-31 アンサン バイオファーマ， インコーポレイテッド Ｄａｓ１８１バリアント組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7334580B2 (en) * 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
EP1539284B1 (en) * 2002-09-06 2020-01-29 Philip Morris Products S.a.s. Aerosol generating device and method for generating aerosols
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
AU2003294401C1 (en) 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
WO2007114881A1 (en) * 2006-01-24 2007-10-11 Nexbio, Inc. Technology for preparation of macromolecular microspheres
AU2010315024B2 (en) * 2009-11-06 2015-02-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract

Also Published As

Publication number Publication date
AU2019226190B2 (en) 2021-10-07
CN109529026A (zh) 2019-03-29
IL273194B2 (en) 2023-02-01
US20130280332A1 (en) 2013-10-24
AU2019226190A1 (en) 2019-09-26
AU2013221230A1 (en) 2014-10-02
EP2841092A4 (en) 2015-09-16
AU2017258955A1 (en) 2017-12-14
US20210046165A1 (en) 2021-02-18
EP2841092C0 (en) 2023-12-06
JP2015508780A (ja) 2015-03-23
HK1207975A1 (en) 2016-02-19
EP2841092A1 (en) 2015-03-04
US20250387457A1 (en) 2025-12-25
US20170151315A1 (en) 2017-06-01
CN104203267A (zh) 2014-12-10
IL273194B (en) 2022-10-01
WO2013123521A1 (en) 2013-08-22
IL234116B (en) 2020-03-31
US20150132274A1 (en) 2015-05-14
IL273194A (en) 2020-04-30
CA2864746A1 (en) 2013-08-22
EP2841092B1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
AU2019226190B2 (en) Methods, compounds and compositions for treatment of influenza and parainfluenza patients
ES2979287T3 (es) Tratamiento de infección respiratoria
ES2887358T3 (es) Inhibidor de Alfa1-Proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
ES2985515T3 (es) Nuevo régimen de dosificación para polipéptido intestinal vasoactivo inhalado
US20120231088A1 (en) Use of Deuterium Oxide for the Treatment of Virus-Based Diseases of the Respiratory Tract
CN111467363A (zh) 索非布韦在制备预防和治疗冠状病毒的药物中的应用
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
CN111407754A (zh) 卡谷氨酸在制备预防和治疗冠状病毒的药物中的应用
WO2011057081A1 (en) Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
CN111420024A (zh) 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
WO2021253647A1 (zh) 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
CN108926707B (zh) Pf4的抗rsv应用
JP2016535782A (ja) 被験者の気道への酵素の投与のための組成物及び方法
CA3119238A1 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
HK1207975B (en) Compounds and compositions for use in a method of treatment of parainfluenza virus
EP4149619A1 (en) Treatment of respiratory viral infections
ES2989089T3 (es) Composición farmacéutica para uso en el tratamiento de enfermedad inducida por virus
EP3906934B1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
EP4611789A1 (en) Sars-cov-2 binding polypeptide
EP4612174A1 (en) Sars-cov-2 binding antibody
WO2022140817A1 (en) Anti-viral proteases and methods of use
CN120829486A (zh) 可有效抗呼吸道rna病毒的多肽类抑制剂及其应用